SEARCH

SEARCH BY CITATION

References

  • 1
    Simson E. Guest editorial: a new hand at the helm. Lab Hematol 2005;11:2367.
  • 2
    Davis BH. Tribute to the founder of ISLH and this journal: Berend Houwen, MD. PhD. Lab Hematol 2004;10:5960.
  • 3
    Philpott K. Our miracle. Central West Region Update (Publication of the Central West Region of Hemophilia Ontario) 2006;4-5. Accessed on line, January 16, 2013 at: http://www.hemophilia.ca/files/CWOR_Fall_06.pdf
  • 4
    Stoskopf MK. Observation and cognition: how serendipity provides the building blocks of scientific discovery. ILAR J 2005;46:3327.
  • 5
    Hayward CP, Smith JW, Horsewood P, Warkentin TE, Kelton JG. p-155, a multimeric platelet protein that is expressed on activated platelets. J Biol Chem 1991;266:711420.
  • 6
    Hayward CP, Warkentin TE, Horsewood P, Kelton JG. Multimerin: a series of large disulfide-linked multimeric proteins in platelets. Blood 1991;77:255660.
  • 7
    Jeimy SG, Tasneem S, Cramer EM, Hayward CP. Multimerin 1. Platelets 2008;19:8395.
  • 8
    Hayward CP, Hassell JA, Denomme GA, Rachubinski RA, Brown C, Kelton JG. The cDNA sequence of human endothelial cell multimerin. A unique protein with RGDS, coiled-coil, and epidermal growth factor-like domains and a carboxyl terminus similar to the globular domain of complement C1q and collagens type VIII and X. J Biol Chem 1995;270:1824651.
  • 9
    Nesheim ME, Furmaniak-Kazmierczak E, Henin C, Cote G. On the existence of platelet receptors for factor V(a) and factor VIII(a). Thromb Haemost 1993;70:806.
  • 10
    Hayward CP, Furmaniak-Kazmierczak E, Cieutat AM, Moore JC, Bainton DF, Nesheim ME, Kelton JG, Côté G. Factor V is complexed with multimerin in resting platelet lysates and colocalizes with multimerin in platelet alpha-granules. J Biol Chem 1995;270:1921724.
  • 11
    Tracy PB, Giles AR, Mann KG, Eide LL, Hoogendoorn H, Rivard GE. Factor V (Quebec): a bleeding diathesis associated with a qualitative platelet Factor V deficiency. J Clin Invest 1984;74:12218.
  • 12
    Hayward CP, Rivard GE, Kane WH, Drouin J, Zheng S, Moore JC, Kelton JG An autosomal dominant, qualitative platelet disorder associated with multimerin deficiency, abnormalities in platelet factor V, thrombospondin, von Willebrand factor and fibrinogen and an epinephrine aggregation effect. Blood 1996;87:496778.
  • 13
    Janeway CM, Rivard GE, Tracy PB, Mann KG. Factor V Quebec revisited. Blood 1996;87:35718.
  • 14
    Hayward CP, Cramer EM, Kane WH, Zheng S, Bouchard M, Masse JM, Rivard GE. Studies of a second family with the Quebec platelet disorder: evidence that the degradation of the alpha-granule membrane and its soluble contents are not secondary to a defect in targeting proteins to alpha-granules. Blood 1997;89:124353.
  • 15
    Blavignanc J, Bunimov N, Rivard GE, Hayward CP. Quebec platelet disorder: update on pathogenesis, diagnosis and treatment. Semin Thromb Hemost 2011;37:71320.
  • 16
    Hayward CP, Rivard GE. Quebec platelet disorder. Expert Review Hematol 2011;4:13741.
  • 17
    McKay H, Derome F, Haq MA, Whittaker S, Arnold E, Adam F, Heddle NM, Rivard GE, Hayward CP. Bleeding risks associated with inheritance of the Quebec platelet disorder. Blood 2004;104:15965.
  • 18
    Hayward CP, Welch B, Bouchard M, Zheng S, Rivard GE. Fibrinogen degradation products in patients with the Quebec platelet disorder. Br J Haematol 1997;97:497503.
  • 19
    Diamandis M, Adam F, Kahr WH, Wang P, Chorneyko KA, Arsenault AL, Rivard GE, Hayward CP. Insights into abnormal hemostasis in the Quebec platelet disorder from analyses of clot lysis. J Thromb Haemost 2006;4:108694.
  • 20
    Kahr WH, Zheng S, Sheth PM, Pai M, Cowie A, Bouchard M, Podor TJ, Rivard GE, Hayward CP. Platelets from patients with the Quebec platelet disorder contain and secrete abnormal amounts of urokinase-type plasminogen activator. Blood 2001;98:25765.
  • 21
    Sheth PM, Kahr WH, Haq MA, Veljkovic DK, Rivard GE, Hayward CP. Intracellular activation of the fibrinolytic cascade in the Quebec platelet disorder. Thromb Haemost 2003;90:2938.
  • 22
    Diamandis M, Paterson AD, Rommens JM, Veljkovic DK, Blavignac J, Bulman DE, Waye JS, Derome F, Rivard GE, Hayward CP. Quebec platelet disorder is linked to the urokinase plasminogen activator gene (PLAU) and increases the expression of the linked allele in megakaryocytes. Blood 2009;113:15436.
  • 23
    Veljkovic DK, Rivard GE, Diamandis M, Blavignac J, Cramer-Borde EM, Hayward CP. Increased expressed of urokinase plasminogen activator in Quebec platelet disorder is linked to megakaryocyte differentiation. Blood 2009;113:153442.
  • 24
    Diamandis M, Veljkovic DK, Derome F, Rivard GE, Hayward CP. Evaluation of urokinase plasminogen activator in urine from individuals with Quebec platelet disorder. Blood Coagul Fibrinolysis 2008;19:4634.
  • 25
    Paterson AD, Rommens JM, Bharaj B, Blavignac J, Wong I, Diamandis M, Waye JS, Derome F, Rivard GE, Hayward CP. Persons with Quebec platelet disorder have a tandem duplication of PLAU, the urokinase plasminogen activator gene. Blood 2010;115:12646.
  • 26
    Hayward CP, Moffat KA, Castilloux JF, Liu Y, Seecharan J, Tasneem S, Carlino S, Cormier A, Rivard GE. Simultaneous measurement of adenosine triphosphate release and aggregation potential human platelet aggregation responses for some subjects, including persons with Quebec platelet disorder. Thromb Haemost 2012;107:72634.
  • 27
    Moffat KA, Ledford-Kraemer MR, Nichols WL, Hayward CP. on behalf of the North American Specialized Coagulation Laboratory Association. Variability in clinical laboratory practice in testing for disorders of platelet function: results of two surveys of the North American Specialized Coagulation Laboratory Association. Thromb Haemost 2005;93:54953.
  • 28
    Cattaneo M, Hayward CP, Moffat KA, Pugliano MT, Liu Y, Michelson AD. Results of a worldwide survey on the assessment of platelet function by light transmission aggregometry; a report from the platelet physiology subcommittee of the SSC of the ISTH. J Thromb Haemost 2009;7:1029.
  • 29
    Hayward CP, Moffat KA, Plumhoff E, Timleck M, Hoffman S, Spitzer E, Van Cott EM, Meijer P. External quality assessment of platelet disorder investigations: results of international surveys on diagnostic tests for dense granule deficiency and platelet aggregometry interpretation. Semin Thromb Hemost 2012;38:62231.
  • 30
    Hayward CP, Moffat KA, Spitzer E, Timleck M, Plumhoff E, Israels SJ, White J. NASCOLA Working Group on Platelet Dense Granule Deficiency. Results of an external proficiency testing exercise on platelet dense-granule deficiency testing by whole mount electron microscopy. Am J Clin Path 2009;131:6715.
  • 31
    Baron JM, Johnson SM, Ledford-Kraemer MR, Hayward CP, Meijer P, Van Cott EM. Protein C assay performance: an analysis of North American specialized coagulation laboratory association testing results. Am J Clin Path 2012;137:90915.
  • 32
    Hayward CP, Moffat KA, Raby A, Israels S, Plumhoff E, Flynn G, Zehnder JL. Development of North American consensus guidelines for medical laboratories that perform and interpret platelet function testing using light transmission platelet aggregometry. Am J Clin Path 2010;134:95563.
  • 33
    Price EA, Hayward CP, Moffat KA, Moore JC, Warkentin TE, Zehnder JL. Laboratory testing for heparin-induced thrombocytopenia is inconsistent in North America: a survey of North American specialized coagulation laboratories. Thromb Haemost 2007;98:135761.
  • 34
    Hayward CP, Moffat KA, Plumhoff E, Van Cott EM. Approaches to investigating common bleeding disorders: an evaluation of North American coagulation laboratory practices. Am J Hematol 2012;97(Suppl 1):S4550.
  • 35
    Moffat KA, Ledford-Kraemer MRN, Plumhoff EA, McKay H, Nichols WL, Meijer P, Hayward CP. Are laboratories following published recommendations for lupus anticoagulant testing? An international evaluation of practices. Thromb Haemost 2009;101:17884.
  • 36
    Nichols WL, Hultin MB, James AH, Manco-Johnson MJ, Montgomery RR, Ortel TL, Rick ME, Sadler JE, Weinstein M, Yawn BP. von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia 2008;14:171232.
  • 37
    Pai M, Moffat KA, Plumhoff E, Hayward CP. Critical values in the coagulation laboratory: results of a survey of the North American Specialized Coagulation Laboratory Association. Am J Clin Pathol 2011;136:83641.
  • 38
    Hayward CP, Eikelboom J. Platelet function testing: quality assurance. Semin Thromb Hemost 2007;33:27382.
  • 39
    Hayward CP, Moffat KA, Pai M, Liu Y, Seecharan J, McKay H, Webert KE, Cook RJ, Heddle NM. An evaluation of methods for determining reference intervals for light transmission platelet aggregation tests on samples with normal or reduced platelet counts. Thromb Haemost 2008;100:13445.
  • 40
    Hayward CP, Pai M, Liu Y, Moffat KA, Seecharan J, Webert KE, Cook RJ, Heddle NM. Diagnostic utility of light transmission platelet aggregometry: results from a prospective study of individuals referred for bleeding disorder assessments. J Thromb Haemost 2009;7:67684.
  • 41
    Pai M, Wang G, Moffat KA, Liu Y, Seecharan J, Webert K, Heddle N, Haywarad C. Diagnostic usefulness of a lumi-aggregometer adenosine triphosphate release assay for the assessment of platelet function disorders. Am J Clin Pathol 2011;136:3508.
  • 42
    Castilloux JF, Moffat KA, Liu Y, Seecharan J, Pai M, Hayward CP. A prospective cohort study of light transmission platelet aggregometry for bleeding disorders: is testing native platelet-rich plasma non-inferior to testing platelet count adjusted samples? Thromb Haemost 2011;106:67582.
  • 43
    Hayward CP, Moffat KA, Liu Y. Laboratory investigations for bleeding disorders. Semin Thromb Hemost 2012;38:74252.